Many Big Winners Are Among Rayno Diagnostics and Tools Stocks in 2014
Abaxis (ABAX) up 46% A major "Point of Care" (POC) Dx Player in veterinary and human markets.
Exact Sciences (EXAS) up 135% An emerging Dx player with non-invasive, DNA based test for colon cancer.
Illumina Inc. (ILMN) up 68% Leading provider of DNA sequencing tools with new paradigm for diagnostics.
Pacific Biosciences (PACB) up 42.6% Emerging DNA sequencing player.
Sequenom (SQNM) up 53.4% Genetic analysis (SNPs) for prenatal testing and other diseases. Spun off bioscience division.
Despite growth of only ~2% in the ~$55B clinical diagnostic market Worldwide in 2013 , new technologies such as sequencing and market niches like POC (Point of Care) and immunoassays provide revenue growth. LDTs (Lab Developed Tests) are also a growth area but the FDA will soon be issuing guidelines for these tests which have limited clinical diagnostic use.The veterinary market segment is also a growth area.
We will review all of our portfolio picks after the 2014 Financial Results. We made two new Dx picks in H2 2014: Foundation Medicine (FMI) at $25 and Pacific Biosciences of California (PACB) at $5.75.
Sign up now to receive 2015 updates on this important sector with a lot of new coming in early 2015.
Here is the complete Rayno Portfolio Summary with April and November Updates:
Diagnostics and Tools Stocks Sold-Off in Q1 But Long Term Outlook Attractive | Raygent.com